Viridian Therapeutics, Inc. (VRDN) Stock Analysis & Investment Frameworks
Viridian Therapeutics, Inc. (VRDN) stock analysis on Invetso. Review Viridian Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Viridian Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Viridian Therapeutics, Inc. Key Financial Metrics
- Market Cap: $2.54B
- Revenue: $70.85M
- ROE: -61.35%
- ROIC: -39.18%
- Dividend Yield: N/A
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. Investment Frameworks
Invetso analyzes Viridian Therapeutics, Inc. (VRDN) across the following frameworks:
- Viridian Therapeutics, Inc. 10Y Growth Potential
- Viridian Therapeutics, Inc. Scenario Analysis
- Viridian Therapeutics, Inc. Risks & Opportunities
- Viridian Therapeutics, Inc. Economic Moat
- Viridian Therapeutics, Inc. Business Model
- Viridian Therapeutics, Inc. Management
- Viridian Therapeutics, Inc. SWOT Analysis
- Viridian Therapeutics, Inc. Porter's 5 Forces
- Viridian Therapeutics, Inc. PESTLE Analysis
- Viridian Therapeutics, Inc. ESG Analysis